Objectives. To estimate the prevalence and consequences of receiving prescription opioids from both the Department of Veterans Affairs (VA) and Medicare Part D.
P rescription opioids claimed more than 183 000 lives in the United States from 2000 to 2015, with millions more suffering the adverse consequences of prescription opioid misuse and abuse. [1] [2] [3] [4] As large payers for prescription drugs, both the Department of Veterans Affairs (VA) and the Centers for Medicare and Medicaid Services (CMS) have invested in monitoring potential misuse and abuse of prescription opioids and have instituted numerous changes to improve opioid safety. 5 These efforts, however, have focused predominately on prescriptions dispensed within their own systems.
Many veterans receive care from both VA and Medicare, in some cases simultaneously. Referred to as "dual use," this receipt of care across health care systems is increasingly common. [6] [7] [8] [9] [10] [11] [12] [13] [14] More than half of veterans enrolled in the VA are also enrolled in Medicare, a third of whom are also enrolled in the Part D drug benefit. 15 While enrollment in both VA and Medicare may increase access to care, it also creates the opportunity for unsafe opioid use because of care fragmentation. As much as CMS and VA have individually done to address opioid use, these efforts have limited capability to assess prescriptions that beneficiaries receive in the other system. This is especially true given that there is no interface between electronic health records (EHRs) across systems and little communication between prescribers or pharmacies. 16 Although the electronic records for care provided through VA and Medicare do not yet communicate, administrative claims data from both are available for research and linkable at the patient level. This enables a national and comprehensive analysis of the impact of dual use on prescription opioids. We thus obtained Medicare and VA data for all dually enrolled veterans who filled a prescription opioid in either system in 2012 to answer 2 previously unanswered questions: (1) What is the national prevalence of dual use of prescription opioids among dually enrolled veterans? and (2) What is the association between dual use of opioids and evidencebased measures of opioid prescribing safety? comprised several domains from the VA Corporate Data Warehouse, including patient demographics and diagnosis codes for all inpatient and outpatient visits, and Pharmacy Benefits Management data for dispensed outpatient prescriptions. The CMS data files included Part D prescription drug events, Medicare Provider Analysis and Review file for inpatient and skilled nursing stays, Beneficiary Summary File for enrollment and sociodemographics, and outpatient and carrier files.
Study Sample
We identified all veterans enrolled in both VA and Medicare Part D in calendar year 2012 who filled at least 1 opioid prescription from either source in 2012 (see Table A , available as a supplement to the online version of this article at http://www.ajph.org, for list of qualifying opioids). We included both Medicare fee-for-service and managed care enrollees in our primary analysis. We excluded veterans in hospice care (n = 28 667) and those solely receiving injection opioids or paregoric or opium tincture (n = 407; Figure  A , available as a supplement to the online version of this article at http://www.ajph. org). For calculations of morphine equivalents, we further excluded 5403 veterans whose sole opioid was either a formulation for which reliable morphine equivalent calculations were unavailable (e.g., oral liquid) or was solely for treatment of substance use disorder (i.e., buprenorphine/naloxone).
Study Outcomes
For each individual, we combined VA and Part D data to calculate the daily prescribed opioid dosage in oral morphine milligram equivalents (MME) by using standard conversion factors at the National Drug Code level from the Centers for Disease Control and Prevention (Table B , available as a supplement to the online version of this article at http://www.ajph.org). 17 In this way, we created an indicator of opioid dosage for each patient for each day of the year. We excluded a small percentage (< 0.5%) of prescriptions from the MME calculation because the quantity dispensed and days supplied were unavailable or unreliable.
We used an "as-prescribed" approach to determine daily dosage, which assumes patients take all prescribed opioids at the dosage and schedule written in the prescription. 18 If a fill was dispensed before the end of the days supplied for the previous prescription, we assumed the patient began the medicine on the dispense date. However, for early refills of the same drug and dosage, we gave a grace period of up to 3 days before that patient would begin the new prescription, making our measure of overlap purposely conservative. We also tested 0-day and 7-day grace periods, with no substantive difference in results (not shown).
Our primary outcomes were 3 measures of potentially unsafe high-dosage opioid use in 2012, each of which are associated with opioid-related adverse events and overdose [18] [19] [20] [21] [22] [23] [24] [25] : (1) the proportion of patients with any day with greater than 100 MME (high opioid dose), (2) mean number of days with greater than 100 MME, and (3) the proportion of patients with a daily dosage of greater than 120 MME for at least 90 consecutive days (long-term, high-dose use). The latter is a Pharmacy Quality Alliance measure included in the Medicaid Adult Core Set of Measures for federal reporting and endorsed by the National Quality Forum. 26 We also created patient-level variables to further describe opioid use, including total number of days receiving an opioid and mean daily MME. To further describe opioid dispensing in the dual-use group, we used the dispense date and days supplied from VA and Part D to categorize dual-use patients into 5 groups according to the number of days of overlap between the opioids they received from VA and Part D: no overlap, 1 to 6 days, 7 to 29 days, 30 to 89 days, and 90 or more days.
Primary Independent Variable and Covariates
Our key independent variable was source of opioid prescriptions in 2012 at the patient level, categorized as VA only, Part D only, or both VA and Part D (i.e., dual use).
We constructed baseline variables for age, gender, enrollment in Medicaid, Part D low-income subsidy, and disability as the original reason for Medicare enrollment. Patient race/ethnicity was captured from VA data, supplemented by the Medicare RTI race/ethnicity indicator when missing from VA. 27 We obtained patient zip code from
Medicare to identify state of residence and matched to the 2012 Area Health Resource File to obtain the county-level urbaninfluence code. 28 We calculated driving distance to the nearest VA primary care site from the VA Public Safety Strategies Group Geocode Enrollee Data.
To account for differences in health status across opioid source groups, we created indicators for number of nonopioid drugs and use of specific medication classes across VA and Part D: sleep aids, muscle relaxants, benzodiazepines, antidepressants, antipsychotics, alcohol dependence medications, and buprenorphine/naloxone. We used these medications as health status indicators in our primary analyses rather than International Classification of Diseases, Ninth Revision (ICD-9), codes because ICD-9 codes are not uniformly available for Medicare managed care enrollees. 29 In a sensitivity analysis (described later in this section), we excluded patients enrolled in Medicare managed care anytime during the year. This allowed us to use ICD-9 codes to capture Elixhauser comorbidities and pain and cancer diagnoses from both VA and Medicare for risk adjustment for the feefor-service population. 30 In these models, we used the total count of Elixhauser comorbidities, excluding alcohol and drug abuse because of restrictions in place prohibiting CMS from releasing substance abuse claims.
Analyses
We used the c 2 test for categorical variables and analysis of variance test for continuous variables to compare baseline characteristics and opioid dispensing patterns across opioid source groups. We also compared our 3 primary opioid safety measures across the 5 categories of days of opioid overlap between VA and Part D within the dual-use group (e.g., 0 days, 1-6 days, 7-29 days).
To examine associations between opioid source and opioid safety measures, we used augmented inverse probability weighting to address potential selection bias and confounding between groups. Augmented inverse probability weighting estimators combine regression adjustment and inverse probability-weighted propensity methods. 31 We first developed inverse probability of treatment weights by using multinomial logistic regression to model the probability of belonging to each of the 3 opioid source groups. Standardized differences between groups in these measured variables were negligible after we applied the weights (Table  C , available as a supplement to the online version of this article at http://www.ajph. org). 32 We used weighted multivariable logistic or linear regression to then model the unsafe opioid use outcomes across opioid source groups. To account for the highly skewed nature of the number of days per year receiving greater than 100 MME, we estimated standard errors and 95% confidence intervals (CIs) by using a bias-corrected bootstrap approach. 33 We report adjusted risk ratios (ARRs) and CIs primarily, but also report odds ratios (ORs) for comparison. 34, 35 We performed 2 sensitivity analyses to assess the robustness of our estimates. First, we excluded individuals with any managed care enrollment and substituted ICD-9-based health status indicators for medication-based indicators. Second, to assess the impact of potentially unobserved confounders, we calculated the value for a hypothetical confounder that would be required to nullify our observed treatment effects. 36 We carried out analyses with SAS version 9.4 (SAS Institute Inc, Cary, NC) and Stata version 14 (StataCorp LP, College Station, TX).
RESULTS
The study cohort comprised 539 473 veterans dually enrolled in VA and Part D with at least 1 opioid prescription dispensed from either source in 2012. Overall, 135 643 (25.1%) received opioids from VA only, 332 630 (61.7%) from Part D only, and 71 200 (13.2%) from both VA and Part D (dual use; Table 1 ). The mean age was 71.5 years, 96.6% were male, and 81.1% were non-Hispanic White. One quarter of the sample was younger than 65 years, and 48.2% were enrolled in managed care.
Veterans with dual use were fairly similar in most characteristics to veterans receiving opioids from VA only. The dual-use group had a greater proportion with White race/ ethnicity, disability as the reason for Medicare enrollment, and enrollment in managed care (Table 1) . Veterans with dual use also used a greater number of medications than did VA-only users (14.4 vs 11.8 nonopioid medications) and were more likely to use each of the specified medication classes (Table 1) . Part D-only recipients were substantially older, more likely to be White, and less likely to be enrolled in Medicaid or eligible for Medicare because of disability.
Unadjusted Opioid Use and Safety by Opioid Source
Veterans with dual use had the greatest number of days on opioids (mean = 220.0), the highest average daily opioid dose (60.2 MME), and were more likely to receive opioids for 90 days or more (77.3%; Table 2 ) compared with the VA-only or Part D-only groups. Part D-only users were least likely to have 90 days or more of use (26.6%).
Veterans with dual use were roughly 3 times more likely to have at least 1 day receiving greater than 100 MME than were veterans with VA-only or Part D-only use (34.3% vs 10.9% and 11.4%, respectively; P < .001; Table 2 ). Compared with the VA-only or Part D-only groups, the dual-use group also had a greater number of days receiving greater than 100 MME (42.5 vs 16.9 days and 12.5 days) and was more likely to have 90 consecutive days receiving greater than 120 MME (7.8% vs 3.1% vs 2.3%; all P < .001).
Among veterans with dual use, 67.5% had at least 1 day in which their VA and Part D opioid prescriptions overlapped, 32.5% had 30 or more days of opioid overlap between VA and Part D, and 18.7% had 90 or more days. Rates of the opioid safety measures increased as the number of days of overlap increased in the dual-use group (Figure 1 ). For example, among those with 90 or more days of overlapping opioid therapy, 70.3% had at least 1 day with greater than 100 MME and 21.6% had 90 consecutive days with greater than 120 MME.
Adjusted Analyses of Opioid Use and Safety by Opioid Source
In adjusted analyses, the dual-use group remained substantially more likely than the VA-only group to have at least 1 day receiving greater than 100 MME (ARR = 3.00; 95% CI = 2.93, 3.06), to have more days with greater than 100 MME (adjusted difference 16.4 days; 95% CI = 15.7, 17.2) and to receive greater than 120 MME for 90 consecutive days (ARR = 2.23; 95% CI = 2.13, 2.33; Table 3 ). The dual-use group also had higher adjusted rates of each measure compared with Part D-only use (Table 3) .
Sensitivity Analyses
Findings were similar in the sensitivity analysis limited to the fee-for-service population using ICD-9 codes to adjust for health status (Table D , available as a supplement to the online version of this article at http:// www.ajph.org). To determine the magnitude of confounding required to nullify our effects, we focused on the outcome with the smallest OR: 90 consecutive days with greater than 120 MME ( Figure B , available as a supplement to the online version of this article at http://www.ajph.org). We used ORs for this calculation consistent with similar previous assessments.
14,36 For comparisons of dual users and VA-only users, a relative risk ratio of greater than or equal to 7 between an unobserved confounder with the outcome would be needed to nullify the observed OR of 2.30. Even if this unobserved confounder met this threshold, an OR of 6.7 or greater between the confounder and dual use would be needed to nullify this significant association.
DISCUSSION
Among veterans dually enrolled in Medicare Part D and VA and receiving prescription opioids in 2012, more than 1 in 8 received opioids from both systems, in many cases concurrently. Compared with VA-only use of opioids, dual use was associated with 3-fold higher risk of high-dose opioid exposure and more than twice the risk of long-term, high-dose opioid exposure. Dual use was also associated with 60% to 90% greater risk of these exposures than was Part D-only use.
These findings highlight a previously undocumented safety issue pertinent to VA and CMS efforts to improve safety of opioid prescribing. Although there are robust decision-support tools within the VA's EHRs that alert providers to high-dose opioid use, this system does not capture prescriptions filled outside VA. Similarly, for non-VA providersand for Medicare administrators-there are no automated systems in place to identify overlapping VA prescriptions. The overlapping prescriptions are not only written by different clinicians, but also dispensed by different pharmacies and reimbursed by different payers.
One option to capture data from both systems is through state Prescription Drug Monitoring Programs (PDMPs), which Note. LIS = low-income subsidy; Q1-Q3 = first to third quartile; VA = Department of Veterans Affairs. Numbers represent column percentage unless otherwise specified. Medicaid and LIS, disability, medication use, and managed care enrollment were assessed in calendar year 2012. Missing data: overall (n = 1853; < 0.05%), race/ethnicity (n = 959), region (n = 25), rurality (n = 49), and driving distance (n = 846). All P values for comparing patient characteristics across the 3 opioid source groups were statistically significant at P < .001. collect dispensing data on opioids from all pharmacies, including most VAs as of 2016.
The Comprehensive Addiction and Recovery Act of 2016 requires VA providers to check PDMP data before starting opioid therapy. 37 However, there are no requirements for PDMP checks before every prescription. There are no similar national requirements for non-VA clinicians, who are subject to varying state laws that govern their use of PDMPs. Moreover, use of PDMPs remains voluntary in most states and requires active log-in and query by clinicians or their surrogates, which is prone to error when compared with automated decision support systems. In states where PDMPs offer automated alerts to clinicians about doctor or pharmacy shopping, 38 routine dual VA and Medicare opioid fills would not be recognized as problematic, given that opioid prescriptions by only 2 providers or 2 pharmacies (in the case of single VA and Medicare prescribers) are unlikely to flag as high risk. 39 Our analysis has implications not only for clinical care but also for policy currently under consideration in the VA. Most importantly, VA is evolving into a less-integrated delivery system-one with more community care options. 40 As this transformation accelerates, the prevalence of poorly coordinated dualsystem care, such as overlapping opioids identified in our analyses or potentially inappropriate drugs identified in a previous analysis, 14 will likely increase. The implications of increasing dual use on quality of care may not be known for years, long after harms materialize. For example, despite the 10 years since Part D's implementation-representing one of the largest-ever expansions in dual care for prescriptions for veterans-we are only now beginning to understand the implications of this expansion on medication safety and outcomes.
There are multiple possible mechanisms by which dual-system use might lead to higher-risk opioid prescribing, although our analysis cannot delineate the direction of causality. Our findings indicate that opioid dosage increased with the number of days of prescription opioid overlap between the 2 systems ( Figure 1 ). This overlap may indicate poorly coordinated care, in which providers who do not communicate and health systems with independent EHR systems enable simultaneous prescribing of duplicate drugs. Multiple previous studies demonstrate risks associated with dual health care system use, often hypothesized to be attributable to poor care coordination. 6, [8] [9] [10] [11] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] Recently, Thorpe et al. identified greater risks of potentially unsafe medication use in dementia patients who receive care across VA and Medicare in a national cohort study, again pointing to problems with care coordination. 14 Another explanation for our observed association is that individuals receiving opioids from multiple systems are purposely seeking higher opioid dosages and multiple prescriptions-that is, those seeking higher opioid dosages or quantities seek out dual use of care. Our analytical approach using augmented inverse probability weighting attempted to balance the dual-use groups as much as possible on factors that may lead patients to seek out higher opioid doses. Given substance use disorder claims redactions by CMS, we were unable to compare the rates of addiction and substance use disorder across groups. However, our analysis accounts for differences in the use of psychiatric medications and medications to treat alcohol and opioid dependence (Table 1 ). In addition, individuals with dual use not only use more of these medications, but they also use more medications in general, making it unlikely that their dual use is solely attributable to seeking opioids. Importantly, even after we accounted for these differences and others (such as pain diagnoses) by using propensity score methods, our sensitivity analysis demonstrated that unmeasured confounding is unlikely to fully explain the Note. MME = morphine milligram equivalents; VA = Department of Veterans Affairs. Numbers represent column percentage unless otherwise specified. All P values for comparisons across the 3 opioid source groups were statistically significant at P < .001.
increased risks associated with dual use of care. Moreover, our study is now in the context of the previous analysis by Thorpe et al., 14 which showed an association between dual use and increased risk of unsafe medication use in patients with dementia-raising the probability that it is not solely the characteristics of individuals who seek out dual use that lead to unsafe medications, but also dual use itself. Regardless of the direction of causality, however, the identified association has clear implications for both VA and CMS in how they each address potentially unsafe opioid use.
Limitations
Our study has important limitations. First, our data are from 2012 and do not represent the current state of opioid use across VA and Medicare. However, this was the most recent year of available data and represents the first comprehensive effort to merge these data to evaluate opioid use. It is important to note that our analyses are broad in scope, including both fee-for-service and managed care enrollees of all ages, representing the entire Part D-VA dually enrolled population. Second, our outcomes are based on safety measures and not medical outcomes. Nevertheless, we selected process measures strongly associated with opioid-related adverse events. Additional analyses are needed to examine the impact of dual use on outcomes including overdose and overdose death. Third, although our primary analysis used select medications and not ICD-9 codes to capture health status (to analyze the entire Medicare-eligible population), our sensitivity analysis limited to the fee-for-service population used ICD-9 comorbidity adjustment and found similar results. Finally, whereas our sample was limited to those dually enrolled in VA and Part D to ensure full capture of all dispensed prescriptions (i.e., no other sources of prescription insurance), we were unable to capture prescriptions paid for in cash dispensed outside the VA, whether illicit or nonillicit, and were unable to know whether patients were taking the dispensed opioid as prescribed.
Conclusions
In this study of all dually enrolled VA and Medicare Part D beneficiaries who filled an opioid prescription in 2012, we documented Note. CI = confidence interval; MME = morphine milligram equivalents; OR = odds ratio; RR = risk ratio; VA = Department of Veterans Affairs. The sample size was n = 532 251 (99.7%); 1819 (0.3%) patients were excluded because of missing data on patients' characteristics including race/ethnicity, driving distance, region, and urban influence. Models were adjusted for age categories, gender, race, Medicaid and low-income subsidy disability, region, urban influence, driving distance to the nearest VA primary care, all individual medications from Note. MME = morphine milligram equivalent; VA = Department of Veterans Affairs. a 3-fold higher risk of high-dose opioid exposure and more than twice the risk of long-term, high-dose opioid exposure among veterans with dual VA and Part D opioid use. As both VA and CMS work to reduce the risks of prescription opioids among their beneficiaries, they must address these opioid safety risks among dual health system users.
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